Rafarma Pharmaceutical news update
Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has...
top of page
Поиск
Rafarma Pharmaceuticals Signed a Preliminary Agreement for Radiopharmaceutical Production Center
Rafarma Pharmaceuticals is pleased to announce that it has signed a preliminary agreement to establish a production center for medical...
Rapharma and Kelun Lifesciences have entered into a preliminary agreement
We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences (Pvt)...
Rafarma Pharmaceuticals plans to open an enterprise in Hong Kong
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce its cooperation with Long Sheng Pharma Limited, a Hong Kong...
Rafarma Pharmaceuticals continues to develop projects on isotopes in Kazakhstan
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) negotiated with The Institute of Nuclear Physics of the Ministry of Energy of the Republic of...
Rafarma Pharmaceuticals is negotiating with an investment fund
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) Chairman of the Board Ilya Shpurov met with the representatives of the investment fund located...
Rafarma Pharmaceuticals met with the Kazakhstan chief specialist in nuclear medicine
Rafarma Pharmaceuticals (OTC: RAFA) representatives held an online meeting with Aigul Saduakasova, a leading radioisotope diagnostics...
Rafarma Pharmaceuticals arranged a meeting with CERES F&D Inc.
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) and Korean biopharmaceutical company CERES F&D planning possible cooperation. Rafarma...
Rafarma Pharmaceuticals negotiated with the Ministry of Kazakhstan
Rafarma Pharmaceuticals, Inc. representatives (OTC: RAFA) met with the Minister of Industry and Infrastructure Development of the...
Rafarma Pharmaceuticals is preparing to participate in a conference dedicated to modern neuroscience
For the fourth time, Rafarma Pharmaceuticals, Inc. (OTC: RAFA) will attend the "Cognitive Science: New Research" conference. Organized by...
Rafarma Pharmaceuticals registered NOYA THERAPEUTICS LTD company in Israel
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) continues to develop business, expand, and strengthen its position in the Israeli market. The...
Letter to the Shareholders from President Raivo Unt
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) shares the following letter to shareholders from President Raivo Unt. It is my pleasure to...
Rafarma Pharmaceuticals plans to build a production unit of pharmacopeial substances in Yeruham
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) entered into negotiations with the Yeruham City Hall and the regulatory authorities of Israel...
Rafarma Pharmaceuticals has entered into negotiations with Israel Ariel University
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) has held a gathering with Ariel University. At the meeting, the parties discussed the...
Rafarma Pharmaceuticals appoints pharmaceutical industry leader Unt Raivo as new CEO
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce the appointment of Raivo Unt as company Chief Executive Officer. Mr. Unt...
Slavich Noya Technology announces H1 2022 results
Slavich Noya Technology, part of the Rafarma Pharmaceuticals (OTC: RAFA) group of companies, shared its achievements, sales and...
Rafarma Pharmaceuticals is continuing to develop smart packaging for a wide range of medicines
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) plans to announce the imminent launch of the most advanced pharmacovigilance and drug logistics...
Rafarma Pharmaceuticals has signed an agreement with Istem Medikal
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) has announced new international cooperation. Representatives of the company visited Turkey and,...
Rafarma Pharmaceuticals strengthens its position in Central Asia
Representatives of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) visited Uzbekistan and discussed the prospects for the company's development...
Rafarma Pharmaceuticals develops new liposome-based medicine for targeted therapy
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) has announced the development of a new drug for colon, pancreas and breast cancer treatment. An...
bottom of page